P&K Skin Research Center Co. Ltd - Asset Resilience Ratio

Latest as of September 2025: 41.86%

P&K Skin Research Center Co. Ltd (347740) has an Asset Resilience Ratio of 41.86% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

₩35.95 Billion
≈ $24.36 Million USD Cash + Short-term Investments

Total Assets

₩85.87 Billion
≈ $58.20 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how P&K Skin Research Center Co. Ltd's Asset Resilience Ratio has changed over time. Check P&K Skin Research Center Co. Ltd (347740) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down P&K Skin Research Center Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 347740 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩35.95 Billion 41.86%
Total Liquid Assets ₩35.95 Billion 41.86%

Asset Resilience Insights

  • Very High Liquidity: P&K Skin Research Center Co. Ltd maintains exceptional liquid asset reserves at 41.86% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

P&K Skin Research Center Co. Ltd Industry Peers by Asset Resilience Ratio

Compare P&K Skin Research Center Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ICON Public Limited Company
F:IJF
Diagnostics & Research 0.00%
Fleury S.A.
SA:FLRY3
Diagnostics & Research 16.06%
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
Diagnostics & Research 0.14%
Diagnósticos da América S.A
SA:DASA3
Diagnostics & Research 10.42%
Cowealth Medical China Co.Ltd.
SHG:603122
Diagnostics & Research 2.25%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%
Cytogen Inc
KQ:217330
Diagnostics & Research 32.97%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%

Annual Asset Resilience Ratio for P&K Skin Research Center Co. Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for P&K Skin Research Center Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 49.62% ₩40.71 Billion
≈ $27.59 Million
₩82.04 Billion
≈ $55.60 Million
-8.11pp
2023-12-31 57.73% ₩44.69 Billion
≈ $30.28 Million
₩77.41 Billion
≈ $52.46 Million
-19.36pp
2022-12-31 77.09% ₩57.46 Billion
≈ $38.94 Million
₩74.54 Billion
≈ $50.51 Million
+14.12pp
2021-12-31 62.97% ₩42.25 Billion
≈ $28.63 Million
₩67.09 Billion
≈ $45.47 Million
-20.05pp
2020-12-31 83.02% ₩49.72 Billion
≈ $33.70 Million
₩59.89 Billion
≈ $40.59 Million
+1.66pp
2019-12-31 81.36% ₩22.76 Billion
≈ $15.42 Million
₩27.97 Billion
≈ $18.95 Million
+16.89pp
2018-12-31 64.47% ₩11.37 Billion
≈ $7.71 Million
₩17.64 Billion
≈ $11.95 Million
--
pp = percentage points

About P&K Skin Research Center Co. Ltd

KQ:347740 Korea Diagnostics & Research
Market Cap
$34.10 Million
₩50.31 Billion KRW
Market Cap Rank
#23263 Global
#1534 in Korea
Share Price
₩1742.00
Change (1 day)
+0.35%
52-Week Range
₩1630.00 - ₩3130.00
All Time High
₩7272.32
About

P&K Skin Research Center Co., Ltd. engages in the evaluation and research of dermatological products in South Korea. It provides scientific information and technical support services for new cosmetic raw material development, functional cosmetics, and human application testing of quasi-drugs. The company performs human application, safety, efficacy, cosmeceuticals, health food, sensory, and in vi… Read more